A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
Status:
Completed
Trial end date:
2020-06-26
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the proportion of adult [greater than or
equal to (>=) 18 years] participants with insomnia disorder taking zolpidem tartrate
immediate release (ZOL-IR) or zolpidem tartrate extended release (ZOL-ER), intermittently or
frequently, who transition to lemborexant 5 milligram (mg) (LEM5) or 10 mg (LEM10) after 2
weeks of receiving LEM.